The stock of Exact Sciences Corporation (NASDAQ:EXAS) last traded at $98.64, up 1.62% from the previous session.
EXAS stock price is now 16.20% away from the 50-day moving average and 61.04% away from the 200-day moving average. The market capitalization of the company currently stands at $17.97B.
With the price target enhanced from $55 to $85, Craig Hallum Upgraded its rating from Hold to Buy for Exact Sciences Corporation (NASDAQ: EXAS).
In other news, Zanotti Katherine S, Director sold 3,027 shares of the company’s stock on Jun 09. The stock was sold for $273,974 at an average price of $90.51. Upon completion of the transaction, the Director now directly owns 64,629 shares in the company, valued at $6.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 09, Director Doyle James Edward sold 1,402 shares of the business’s stock. A total of $126,895 was realized by selling the stock at an average price of $90.51. This leaves the insider owning 54,110 shares of the company worth $5.34 million. Insiders disposed of 122,747 shares of company stock worth roughly $12.11 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EXAS stock. A new stake in Exact Sciences Corporation shares was purchased by JENNISON ASSOCIATES LLC during the first quarter worth $43,296,000. TWINBEECH CAPITAL LP invested $27,344,000 in shares of EXAS during the first quarter. In the first quarter, ARDEVORA ASSET MANAGEMENT LLP acquired a new stake in Exact Sciences Corporation valued at approximately $19,343,000. HHLR ADVISORS, LTD. acquired a new stake in EXAS for approximately $16,778,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. purchased a new stake in EXAS valued at around $15,778,000 in the second quarter. In total, there are 783 active investors with 89.30% ownership of the company’s stock.
With an opening price of $97.68 on Thursday morning, Exact Sciences Corporation (NASDAQ: EXAS) set off the trading day. During the past 12 months, Exact Sciences Corporation has had a low of $29.27 and a high of $99.00. As of last week, the company has a debt-to-equity ratio of 0.78, a current ratio of 3.00, and a quick ratio of 2.60. The fifty day moving average price for EXAS is $85.59 and a two-hundred day moving average price translates $61.58 for the stock.
The latest earnings results from Exact Sciences Corporation (NASDAQ: EXAS) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.42, beating analysts’ expectations of -$0.75 by 0.33. This compares to -$1.04 EPS in the same period last year. The net profit margin was -23.50% and return on equity was -16.60% for EXAS. The company reported revenue of $602.45 million for the quarter, compared to $486.57 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.82 percent. For the current quarter, analysts expect EXAS to generate $600.14M in revenue.
Exact Sciences Corporation(EXAS) Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
